Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2026
Business Overview: Humana is a leading U.S. healthcare company operating through two primary segments: Insurance (Medicare, Medicaid, and specialty benefits) and CenterWell (pharmacy, primary care, and home solutions). The company focuses on an integrated care delivery model to improve health outcomes and affordability.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $39,648 | $32,112 |
| Net Income Attributable to Humana | $1,186 | $1,244 |
| Diluted Earnings Per Share (EPS) | $9.83 | $10.30 |
| Operating Cash Flow | $1,254 | $331 |
| Cash and Cash Equivalents (End of Period) | $4,951 | $4,250 |
| Total Debt (Short-term + Long-term) | $13,993 | $12,369 |
| Benefit Ratio | 89.4% | 87.0% |
| Operating Cost Ratio | 10.2% | 10.6% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 23.5% to $39.6 billion, driven by a 23.6% increase in premiums revenue. This growth was primarily due to membership expansion across Medicare businesses and higher per-member premiums resulting from increased CMS benchmark funding and Part D direct subsidies under the Inflation Reduction Act.
- Profitability Decline: Net income decreased 4.7% to $1.2 billion. Income from operations fell 12.9% to $1.8 billion. The decline was impacted by a 240 basis point increase in the benefit ratio (to 89.4%) and valuation adjustments related to non-consolidating minority interest investments.
- Acquisition Activity: Humana acquired MaxHealth, a Florida-based primary care organization, for approximately $908 million in cash. This resulted in $800 million of goodwill and $71 million of other intangible assets.
- Debt Issuance: In March 2026, the company issued $1.0 billion in 6.625% junior subordinated notes due 2056, generating $990 million in net proceeds. Short-term debt increased to $1.7 billion, primarily due to commercial paper issuances.
- Value Creation Charges: The company recorded $98 million in charges related to value creation initiatives (severance, consulting, asset impairments), compared to $24 million in the prior year.
Outlook, Risks, and Contingencies
- Regulatory Litigation (RADV): A significant contingency involves the Centers for Medicare and Medicaid Services (CMS) Risk-Adjustment Data Validation (RADV) audits. Humana successfully vacated the "Final RADV Rule" in September 2025, but the government has appealed the decision. The outcome remains uncertain and could materially impact financial results if extrapolated recoveries without a Fee-for-Service Adjuster are applied retroactively.
- Star Ratings: The company faces a revenue headwind in 2026 due to Bonus Year (BY) 2026 Star Ratings. Humana is also appealing a court decision rejecting its challenge to the 2025 Star Ratings methodology.
- Legal Proceedings: The company is defending against a stockholder class action regarding financial performance statements and a qui tam lawsuit involving non-commission payments to broker partners.
- Transformation Program: Management is executing a multi-year transformation program to re-align cost structures. Additional charges are expected over the course of this program.
- Liquidity: The company maintains a BBB credit rating (S&P) and Baa2 (Moody's). It has $4.99 billion of remaining borrowing capacity under its revolving credit agreement and $2.7 billion remaining in its share repurchase authorization.
Investor Verification Checklist
- Regulatory Appeal Status: Monitor the status of the appeal in Humana v. Kennedy regarding the RADV rule, as a reversal could trigger significant financial liabilities.
- Benefit Ratio Trends: Verify if the 89.4% benefit ratio stabilizes in subsequent quarters, given the headwinds from new member acquisition costs and Star Rating impacts.
- MaxHealth Integration: Assess the financial integration and performance of the MaxHealth acquisition in future quarters to ensure it meets projected value creation goals.
- Debt Servicing: Review the impact of the new $1.0 billion junior subordinated notes and commercial paper usage on future interest expense and cash flow.
- Value Creation Charges: Track the magnitude of future charges associated with the transformation program to gauge the full impact on operating margins.